Uveal Melanoma Therapeutics Pipeline Analysis Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body. The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. 

 

The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.

 

Download the sample report @ https://www.pharmaproff.com/request-sample/1121

 

The drug candidates of uveal melanoma disease pipeline include, but not limited to, nivolumab and IMCgp100. Some of the companies having drugs in the uveal melanoma therapeutics pipeline includes Harmonic Pharma, Immunocore Ltd. and Celldex Therapeutics, Inc.